Biotech Values

[DewDiligence]

NLTX reverse-merges with—(private)—Neurogene Inc:

https://www.globenewswire.com/news-release/2023/07/18/2706252/0/en/Neurogene-and-Neoleukin-Announce-Definitive-Merger-Agreement.html

Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company and pre-merger Neurogene stockholders (including those purchasing Neurogene shares in the concurrent private financing discussed above) are expected to own approximately 84% of the combined company.

…Upon closing of the proposed transaction, Neoleukin Therapeutics, Inc., will be renamed Neurogene Inc. The combined company will be led by Rachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene, and other members of the Neurogene management team.

…Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. …The company’s novel and proprietary EXACT gene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy.

The Nasdaq ticker symbol will presumably be changed when the merger closes.